## Distinguishing Zollinger-Ellison Syndrome from Hyperparathyroidism-Associated Acid Hypersecretion **Key Point:** The **secretin stimulation test** is the gold-standard discriminator between ZES and other causes of hypergastrinemia including primary hyperparathyroidism (pHPT)-associated acid hypersecretion. In ZES, secretin causes a **paradoxical rise in serum gastrin ≥200 pg/mL above baseline** — a pathognomonic finding. In pHPT, secretin **suppresses or does not change** gastrin, because the G cells retain normal feedback regulation. ### Why Option C is Correct The stem explicitly states the patient has a **paradoxical rise in serum gastrin on secretin stimulation** — this is the defining diagnostic test for ZES. Option C directly captures this discriminating feature: - **ZES:** Secretin paradoxically stimulates the gastrinoma (which has lost normal feedback inhibition) → gastrin rises ≥200 pg/mL above baseline - **pHPT:** Secretin acts on normal G cells, which respond physiologically → gastrin suppresses or remains unchanged This is the **single most specific test** to distinguish ZES from all other causes of hypergastrinemia, including pHPT-associated hypercalcaemia (Harrison's Principles of Internal Medicine, 21st ed.; Feldman: Sleisenger and Fordtran's Gastrointestinal and Liver Disease). ### Why Option B is Incomplete as the "Best Distinguishing Feature" Option B describes the **pathophysiological mechanism** (tumour-derived gastrin vs. hypercalcaemia-stimulated G cells), which is conceptually correct but is **not the best clinical discriminator** in this context. The question asks for the feature that "best distinguishes" the two conditions — in clinical practice, the secretin stimulation test (Option C) is the definitive, operationally specific discriminator, not the mechanistic description. Furthermore, Option B's framing ("hyperparathyroidism causes acid hypersecretion via hypercalcaemia-stimulated gastrin release") is an oversimplification; hypercalcaemia also directly stimulates parietal cells independent of gastrin. ### Comparison Table | Feature | Zollinger-Ellison Syndrome | pHPT + Acid Hypersecretion | |---|---|---| | **Primary Pathology** | Gastrin-secreting neuroendocrine tumour | Parathyroid adenoma/hyperplasia | | **Fasting Gastrin** | Often >1000 pg/mL (can be 240–1000 in mild/early cases) | Usually <200 pg/mL or normal | | **Serum Calcium** | Normal | **Elevated** | | **Serum PTH** | Normal | **Elevated** | | **Secretin Stimulation** | **Paradoxical rise ≥200 pg/mL** *(pathognomonic)* | **Suppression or no change** | | **PPI Response** | Requires high-dose (40–80 mg BID) | Responds to standard-dose | **High-Yield:** The secretin stimulation test is positive (paradoxical gastrin rise) **only in ZES** — it does not occur in pHPT, antral G-cell hyperplasia, or other causes of hypergastrinemia. A rise of ≥200 pg/mL above baseline within 10 minutes of IV secretin (2 U/kg) is diagnostic (sensitivity ~85%, specificity ~100%). **Clinical Pearl:** Approximately **25% of gastrinomas occur in the setting of MEN-1** (multiple endocrine neoplasia type 1), which also includes pHPT as its most common manifestation. In MEN-1, both ZES and pHPT may coexist — the secretin stimulation test remains the key tool to confirm the gastrinoma component. **Note on gastrin level:** A fasting gastrin of 240 pg/mL (as in this patient) is above normal but below the classic ZES threshold of >1000 pg/mL. In such borderline cases, the secretin stimulation test is especially critical for diagnosis, reinforcing why Option C is the best discriminating feature. **Reference:** Harrison's Principles of Internal Medicine, 21st ed., Chapter on Peptic Ulcer Disease and Related Conditions; Feldman: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th ed.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.